

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Diabetes

**Manuscript NO:** 63806

**Title:** Clinical Effects of Antidiabetic Drugs on Psoriasis: The Perspective of Evidence-based Medicine

**Reviewer's code:** 02476743

**Position:** Editorial Board

**Academic degree:** PhD

**Professional title:** Associate Professor, Director, Statistician

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-03

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-02-04 00:53

**Reviewer performed review:** 2021-02-04 01:12

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

From the evidence-based medicine viewpoint, the current evidence demonstrates therapeutic efficacy of pioglitazone, which may be a treatment option in patients with psoriasis and diabetes mellitus. This inspiring result may also indicate that for those patients with both diabetes and psoriasis, pioglitazone may be the optimal choice for treatment. I would like to congratulate the authors for the enthusiasm invested in this editorial.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Diabetes

**Manuscript NO:** 63806

**Title:** Clinical Effects of Antidiabetic Drugs on Psoriasis: The Perspective of Evidence-based Medicine

**Reviewer's code:** 05564292

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-03

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2021-02-04 14:28

**Reviewer performed review:** 2021-02-04 18:09

**Review time:** 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

It was my pleasure to review this (invited) editorial describing the role of several antidiabetic drug classes in psoriasis, a common comorbidity of type 2 diabetes. The article is nicely written and shows the authors' concise effort to inform their readers about the potential antipsoriatic effects of TZDs, metformin and GLP1 receptor agonists, and the need for adequately powered and long-term studies. Although the editorial is presented in detail and with most of the relevant information, I would consider minor changes in a revised version: -The mechanisms of GLP1 receptor agonists that determine their antihyperglycemic and anti-inflammatory effects should be briefly mentioned and refereced (i.e. Int J Environ Res Public Health. 2020 May 22;17(10):3664. doi: 10.3390/ijerph17103664.) -"The microenvironment such as inflammation and insulin resistance, as well as genes and epigenetic changes may commonly contribute to the two diseases", this sentence should be properly rephrased. An altered adipose tissue microenvironment in obesity is responsible for insulin resistance and low-grade inflammation at either local or systemic level (e.g. skin). That said, diabetes can relate with a wide spectrum of skin conditions, including but not limited to psoriasis, due to hyperglycemia-induced microvascular damage, altered immune functions, infections, genetic predisposition, etc. In my opinion, this section would benefit of short but deeper insights into the etiological and pathophysiological mechanisms that specifically link diabetes to psoriasis (in all its variants).

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Diabetes

**Manuscript NO:** 63806

**Title:** Clinical Effects of Antidiabetic Drugs on Psoriasis: The Perspective of Evidence-based Medicine

**Reviewer's code:** 05564292

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-03

**Reviewer chosen by:** Man Liu

**Reviewer accepted review:** 2021-04-12 16:15

**Reviewer performed review:** 2021-04-12 16:21

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

Manuscript has been improved according to the reviewer's comments.